Characteristics, Healthcare Utilization, and Costs of Medicare Patients Receiving CAR T-Cell Therapy

Video

Karl M. Kilgore, PhD, senior research scientist, Avalere Health, discusses real-world data regarding Medicare patients with non-Hodgkin lymphoma receiving CAR T-cell therapy.

Karl M. Kilgore, PhD, senior research scientist, Avalere Health, discusses real-world data regarding Medicare patients with non-Hodgkin lymphoma receiving CAR T-cell therapy.

In the analysis, investigators compared healthcare utilization, costs, and outcomes pre- and post-treatment with either axicabtagene ciloleucel (axi-cel; Yescarta) or tisagenlecleucel (Kymriah). Patients included in the analysis had an average age of 70 years, which is significantly older than the patients enrolled in the pivotal trials, notes Kilgore. Notably, 43% of patients had ≥1 comorbidity that would have rendered them ineligible for participation in these clinical trials.

Even so, investigators found a significantly lower hospital stay rate following treatment with CAR T-cell therapy. Moreover, the number of emergency department visits was reduced by 30%, and the total healthcare costs, excluding the cost of CAR T-cell therapy, was reduced by approximately 37%. Taken collectively, these results suggest that older patients with multiple comorbidities can be treated successfully with CAR T-cell therapy, concludes Kilgore.

Related Videos
Paul Harmatz, MD
Mark Walters, MD
Mitchel Horwitz, MD
Bruce Cree, MD, PhD, MAS, a professor of neurology and the clinical research director of the University of California San Francisco (UCSF) Multiple Sclerosis Center
Emilie Aschenbrenner, PharmD, BCOP, a hematology coordinator for pharmacy at Froedtert and the Medical College of Wisconsin
Raj Chovatiya, MD, PhD
Jessica S. Little, MD, a transplant infectious diseases physician at Dana-Farber Cancer Institute
Nirav N. Shah, MD
Alexis Kuhn, PharmD, BCOP, a pediatric oncology pharmacist at the Mayo Clinic
Haydar Frangoul, MD
© 2024 MJH Life Sciences

All rights reserved.